Thus, the role of MERTK in mediating immune tolerance and its association with HLA-DR15 in MS risk suggest that the MERTK genotype and its expression profile on innate immune cells may influence the efficacy of tolDC therapy in MS. Here, MERTK is linked to myeloid sarcoma.